7 results on '"Ravano, E"'
Search Results
2. PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY
- Author
-
Alfredo Molteni, Emanuele Ravano, Mauro Truini, Roberto Cairoli, Marta Riva, Laura Bandiera, Lara Crucitti, Michele Nichelatti, Molteni, A, Ravano, E, Riva, M, Nichelatti, M, Bandiera, L, Crucitti, L, Truini, M, and Cairoli, R
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,p53 expression ,Prognosi ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Biopsy ,medicine ,Overall survival ,MDS ,Mutational status ,In patient ,P53 expression ,medicine.diagnostic_test ,business.industry ,lcsh:RC633-647.5 ,Myelodysplastic syndromes ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,Immunohistochemistry ,Original Article ,Bone marrow ,prognosis ,business - Abstract
Background and objectives: Mutations of the TP53 gene have an unfavorable prognosis in Myelodysplastic Syndromes (MDS). The product of the TP53gene is the p53 protein. Most of TP53mutations entail the accumulation of the protein in the nucleus of tumor cells. The immunohistochemical (IHC) staining for p53 can be a surrogate suggesting a mutational status and, if overexpressed, seems to be of prognostic value by itself. The best prognostic cut-off value of overexpression is controversial. The aim of this pilot study is to investigate about the correct value from a homogenous group of patients with higher IPSS-R risk MDS. Methods: In sixty consecutive patients diagnosed with MDS and categorized as IPSS-R risk “intermediate”, “high” and “very high”, the bone marrow biopsies performed at the diagnosis were retrospectively re-examined for IHC p53 expression. The result of p53 expression was subsequently related to survival. Results: A worst overall survival was observed both in patients whose IHC p53 expression was ≥5% and ≥ 10% compared to the patients with a p53 expression respectively below 5% (p= 0.0063) or 10% (p=0.0038). Conclusions: The ICH p53 expression in bone marrow biopsy in higher risk MDS was confirmed to have prognostic value. These results indicate more than 10% expression as the best cut off value.
- Published
- 2019
3. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes
- Author
-
Roberto Cairoli, Rosa Greco, Silvano Rossini, Valentina Speziale, Marta Riva, Michele Nichelatti, Enrica Morra, Barbara Scarpati, Alfredo Molteni, Emanuele Ravano, Clara Cesana, Molteni, A, Riva, M, Cesana, C, Speziale, V, Nichelatti, M, Scarpati, B, Greco, R, Ravano, E, Cairoli, R, Rossini, S, and Morra, E
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Pathology ,Immature cells ,CD33 ,CD34 ,Bone Marrow Cells ,Cell Count ,Blast Count ,Immunophenotyping ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Retrospective analysis ,Humans ,In patient ,Medullar blasts count ,Aged ,Aged, 80 and over ,biology ,CD117 ,business.industry ,Myelodysplastic syndromes ,Bone Marrow Examination ,Hematology ,General Medicine ,Middle Aged ,Flow Cytometry ,Prognosis ,medicine.disease ,Myelodysplastic Syndromes ,biology.protein ,Female ,business ,Myelodysplastic syndrome ,Prognostic assessment ,Biomarkers - Abstract
Objective The medullar blast count is a milestone in the prognostic assessment in myelodysplastic syndromes (MDS). The optical microscopy (OM) may sometimes be inaccurate in this disease. The aim of this work is to test the flow immunocytometric (FCM) determinations of medullar immature cells (CD45±) and the expression, among them, of CD33, CD34, and CD117 markers, for their prognostic relevance. Methods In a retrospective analysis of 98 patients affected by MDS, the IPSS was re-calculated by means of the FCM determination of blasts. Survival of patients at low or intermediate-1 IPSS risk was compared with the survival of patients at intermediate-2 or high IPSS risk. In the 64 cases with OM blast count lower than 5%, the survival of patients with the FCM count of medullar blasts ≤2% was compared with that of patients with FCM count >2%. Results Each single marker had a prognostic weight comparable to the optical blast count. The FCM blast count was particularly efficient in distinguishing the risk of having up to 2% or more than 2% of blasts in patients without OM excess of blasts. Conclusion This method is interesting as prognostic tool, especially in patients without excess of blast.
- Published
- 2014
4. A PROPOSAL OF MULTI-DIMENSIONAL EVALUATION OF ELDERLY PATIENTS AFFECTED BY MDS: THE 'NO-CHAIN' ALGORITHM
- Author
-
Roberto Cairoli, Marta Riva, Alfredo Molteni, Emanuele Ravano, Riva, M, Ravano, E, Cairoli, R, and Molteni, A
- Subjects
Cancer Research ,medicine.medical_specialty ,Physical medicine and rehabilitation ,Theoretical computer science ,Chain (algebraic topology) ,Oncology ,Computer science ,medicine ,Multi dimensional ,Hematology - Published
- 2017
5. Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience
- Author
-
Emanuele Ravano, Roberto Cairoli, Marta Riva, Alfredo Molteni, Lara Crucitti, Michele Nichelatti, Cristina Fiamenghi, Gianluigi Reda, Riva, M, Crucitti, L, Ravano, E, Nichelatti, M, Reda, G, Fiamenghi, C, Cairoli, R, and Molteni, A
- Subjects
Response rate (survey) ,Danazol ,medicine.medical_specialty ,business.industry ,Myelodysplastic syndromes ,Immunology ,Eltrombopag ,Repeated measures design ,Cell Biology ,Hematology ,medicine.disease ,Lower risk ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Hypocellularity ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Adverse effect ,business ,030215 immunology ,medicine.drug - Abstract
Background: Severe thrombocytopenia is an uncommon event in patients (pts) with lower-risk MDS, but it may significantly affect the prognosis. No specific pharmacological approaches other than hypometilating agents (not licensed in Europe in lower-risk MDS), able to improve platelet count in this setting, are currently available. Trials testing efficacy and safety of Eltrombopag are ongoing (Oliva 2017). Few data were reported about danazol, an attenuated androgen, that seems to have also some effectiveness in this still unmet need (Wattel 1994; Chan 2002). Aims: To assess the efficacy and safety of danazol in improving the platelet count in low risk MDS pts with severe thrombocytopenia. Methods: We retrospectively reviewed 35 thrombocytopenic MDS pts treated with danazol. The initial and maximal dose was 600 mg/day for all pts, modulated according to response and toxicity. The response was evaluated according to IWG response criteria (Cheson 2006). The outcome was strictly observed every 3 months (mo) up to the 12th mo, and the platelets average number in each observation moment was described. The time to response, the response rate and the enduring of response were also recorded. Results: Of the 35 pts, according to 2016 WHO classification, 4 pts were MDS-ULD; 19 were MDS-MLD (3 of them with medullar hypocellularity), 7 were MDS-EB1 and 5 were affected by MDS/MPN. At baseline the platelet count was lower than 20x10^3/mL in 11 pts, the median was 23x10^3/mL . At starting time of danazol therapy the IPSS-R cytogenetic class of risk was very low in 2 cases, low in 28 cases, intermediate in 3 cases and very high in 1 case. Cytogenetic was not available in one patient. In the 30 MDS pts, the IPSS-R was "very low" in 1 patient, "low" in 16, "intermediate" in 7, "high" in 4 and "very high" in 1. In 1 case it was not evaluable due to the lack of cytogenetics. Two pts were not included in the analysis because they were treated for less than 3 mo (in 1 case danazol was withdraw to permit the beginning of another therapy and in 1 case due to death for other neoplastic disease). The response rate was 63,6% (21 responders on 33 evaluable). Median time to response was 3.5 mo (range 0.3 - 12.4 mo); the average response time was 5.09 mo. In the first year of treatment, the platelet count (evaluated at baseline, 3, 6, 9 and 12 mo) changed in a significant way (F test after repeated measures ANOVA: p < 0.001 as shown in Figure 1). Pairwise comparisons of platelet count according to Bonferroni showed a significant difference for baseline vs. 3 mo (p = 0.0013), baseline vs 6 mo (p = 0.0255), baseline vs 9 mo (p = 0.0047) and baseline vs 12 mo (p = 0.0014); however, no significant differences (p ≥ 0.05) in counts were seen for all the further pairwise comparisons at 3, 6, 9 and 12 mo. The median and average duration of the response for the entire population were respectively 12,5 and 32,5 mo. Only 6 of the 21 responders (28%) lost the response (the median and average duration of response were respectively 5.8 and 12.9 mo). Within the 21 responders, the median progression free survival was not reached after 24 mo. The probability to maintain the response after 50 mo was assessed at 58.2% (C.I. 24.1% to 81.4% - Figure 2). The overall survival showed a significant difference (logrank test: p = 0.0064) between responders and non-responders (Figure 3). Adverse events recorded were as follows: moderate (grade 1 and 2) increase in transaminases in 4 cases (with reduction of danazol to 400 mg/day); 1 case of severe but reversible liver toxicity (grade 3) (with subsequently drug suspension); severe (grade 3) but reversible renal failure in 1 case (the drug was stopped); moderate (grade 1 and 2) increasing of serum creatinine in 6 case (with reduction of danazol to 400 mg/day in 2 of these); reversible cutaneous rash in 3 cases; amenorrhea in 1 case (the only fertile woman in the series); weight loss and loss of appetite in 1 case, weight gain in 1 case. Conclusion: Even if the mechanism of action of danazol in pts with MDS is unclear, this series confirms its efficacy to improve platelet count in the most of MDS pts with severe thrombocytopenia. The response was often clinically significant. It may not be immediate but seems to be reachable after 3-6 mo of treatment. A responsive patient has a good probability to maintain a long-lasting response. The toxicity profile of this drug is acceptable. Waiting for more effective options, danazol may be a good therapeutic option for these pts. Disclosures Riva: Jannsen and Cilag: Consultancy; Novartis: Consultancy; Celgene: Consultancy. Reda:Celgene: Consultancy; Janssen and Cilag: Consultancy; Gilead: Consultancy; ABBVIE: Consultancy. Molteni:AMGEN: Consultancy; Novartis: Consultancy; Italfarmaco: Consultancy; Celgene: Consultancy; Janssen and Cilag: Consultancy.
- Published
- 2018
6. Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience
- Author
-
Roberto Cairoli, Marta Riva, Emanuele Ravano, Rosa Greco, Alfredo Molteni, Valentina Mancini, Giovanni Grillo, Laura Marbello, Elisa Zucchetti, Molteni, A, Riva, M, Ravano, E, Marbello, L, Mancini, V, Grillo, G, Zucchetti, E, Greco, R, and Cairoli, R
- Subjects
Adult ,Male ,medicine.medical_specialty ,Relapsed/refractory AML ,Adolescent ,medicine.medical_treatment ,Salvage therapy ,Hematopoietic stem cell transplantation ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,medicine ,Clofarabine ,Humans ,Etoposide ,Aged ,Retrospective Studies ,Salvage Therapy ,Mitoxantrone ,Chemotherapy ,business.industry ,Adenine Nucleotides ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Allografts ,Surgery ,Fludarabine ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,Cytarabine ,Female ,Arabinonucleosides ,business ,Vidarabine ,030215 immunology ,medicine.drug - Abstract
For refractory or relapsed acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation is the only curative treatment option, but the disease must be in remission before this can be attempted. “Salvage” therapy regimens containing high-dose cytarabine plus fludarabine or cladribine with or without anthracyclines or plus mitoxantrone and etoposide fail in 30–50% of cases. We report the outcome of 14 patients treated with a clofarabine-based treatment administered after at least one failed fludarabine-based “salvage” attempt in a “real life” (outside a clinical trial) context. No death related to the clofarabine-based treatment was observed. Four of the 14 patients (29%) reached complete remission and one (7%) achieved a reduction of marrow blasts to fewer than 10%. Three of these five patients were successfully transplanted and have shown a long-term survival. The small number of this group of patients does not permit the identification of clinical features clearly related to a favorable outcome, but we note that all the three long-term survivals were FLT3 wild type. Clofarabine-based “salvage therapy” in patients with very poor expectancy is feasible even after a fludarabine-based salvage attempt, albeit with success only in a small percentage of cases (3/14 = 21%).
- Published
- 2016
7. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the 'Rete Ematologica Lombarda'
- Author
-
Alessandra Freyrie, Emanuele Ravano, Enrica Morra, Roberto Cairoli, Jacopo Mariotti, Marta Ubezio, Rosa Greco, Matteo G. Della Porta, Domenica Caramazza, Massimo Bernardi, Marta Riva, Simona Guarco, Alfredo Molteni, Lorenza Borin, Giulia Quaresmini, Michele Nichelatti, Federica Gigli, Anna Maria Pelizzari, Molteni, A, Riva, M, Borin, L, Bernardi, M, Pelizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, and Morra, E
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Azacitidine ,Disease ,Comorbidity ,Kaplan-Meier Estimate ,Prognostic indice ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Young adult ,Psychiatry ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Myelodysplastic syndromes ,Retrospective cohort study ,5-Azacytidine ,Hematology ,Middle Aged ,medicine.disease ,Leukemia, Myeloid, Acute ,Oncology ,ROC Curve ,International Prognostic Scoring System ,030220 oncology & carcinogenesis ,Myelodysplastic Syndromes ,High risk myelodysplastic syndrome ,Oligoblastic acute myeloid leukemia ,Female ,business ,Risk assessment ,030215 immunology ,medicine.drug - Abstract
5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.